Evolent Health Net Income
| EVH Stock | USD 2.79 0.15 5.68% |
As of the 15th of February 2026, Evolent Health shows the Standard Deviation of 3.86, mean deviation of 2.75, and Variance of 14.86. Evolent Health technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.
Evolent Health Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 0.6217 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -55.5 M | -58.2 M | |
| Net Loss | -55.5 M | -58.2 M | |
| Net Loss | -84.1 M | -88.3 M | |
| Net Loss | (0.62) | (0.65) | |
| Net Income Per E B T | 1.12 | 0.96 |
Evolent | Net Income | Build AI portfolio with Evolent Stock |
The Net Income trend for Evolent Health offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Evolent Health is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Evolent Health's Net Income Growth Pattern
Below is the plot of the Net Income of Evolent Health over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Evolent Health financial statement analysis. It represents the amount of money remaining after all of Evolent Health operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Evolent Health's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Evolent Health's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (61.62 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Evolent Net Income Regression Statistics
| Arithmetic Mean | (57,936,614) | |
| Coefficient Of Variation | (242.31) | |
| Mean Deviation | 80,466,404 | |
| Median | (52,658,000) | |
| Standard Deviation | 140,388,242 | |
| Sample Variance | 19708.9T | |
| Range | 666.7M | |
| R-Value | (0.28) | |
| Mean Square Error | 19390.2T | |
| R-Squared | 0.08 | |
| Significance | 0.28 | |
| Slope | (7,747,294) | |
| Total Sum of Squares | 315341.7T |
Evolent Net Income History
Other Fundumenentals of Evolent Health
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Evolent Health Net Income component correlations
Evolent Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Evolent Health is extremely important. It helps to project a fair market value of Evolent Stock properly, considering its historical fundamentals such as Net Income. Since Evolent Health's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Evolent Health's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Evolent Health's interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Health Care Technology market expansion? Will Evolent introduce new products? Factors like these will boost the valuation of Evolent Health. Projected growth potential of Evolent fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Evolent Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.57) | Revenue Per Share | Quarterly Revenue Growth (0.23) | Return On Assets | Return On Equity |
Understanding Evolent Health requires distinguishing between market price and book value, where the latter reflects Evolent's accounting equity. The concept of intrinsic value - what Evolent Health's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Evolent Health's price substantially above or below its fundamental value.
It's important to distinguish between Evolent Health's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Evolent Health should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Evolent Health's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Evolent Health 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Evolent Health's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Evolent Health.
| 11/17/2025 |
| 02/15/2026 |
If you would invest 0.00 in Evolent Health on November 17, 2025 and sell it all today you would earn a total of 0.00 from holding Evolent Health or generate 0.0% return on investment in Evolent Health over 90 days. Evolent Health is related to or competes with Nutex Health, HealthStream, AMN Healthcare, Myriad Genetics, Replimune, ArriVent BioPharma, and MeiraGTx Holdings. Evolent Health, Inc., a healthcare company, through its subsidiary, Evolent Health LLC, provides clinical and administra... More
Evolent Health Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Evolent Health's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Evolent Health upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.22) | |||
| Maximum Drawdown | 20.55 | |||
| Value At Risk | (7.42) | |||
| Potential Upside | 4.51 |
Evolent Health Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Evolent Health's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Evolent Health's standard deviation. In reality, there are many statistical measures that can use Evolent Health historical prices to predict the future Evolent Health's volatility.| Risk Adjusted Performance | (0.16) | |||
| Jensen Alpha | (0.84) | |||
| Total Risk Alpha | (1.09) | |||
| Treynor Ratio | (1.16) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Evolent Health's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Evolent Health February 15, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.16) | |||
| Market Risk Adjusted Performance | (1.15) | |||
| Mean Deviation | 2.75 | |||
| Coefficient Of Variation | (487.70) | |||
| Standard Deviation | 3.86 | |||
| Variance | 14.86 | |||
| Information Ratio | (0.22) | |||
| Jensen Alpha | (0.84) | |||
| Total Risk Alpha | (1.09) | |||
| Treynor Ratio | (1.16) | |||
| Maximum Drawdown | 20.55 | |||
| Value At Risk | (7.42) | |||
| Potential Upside | 4.51 | |||
| Skewness | (0.20) | |||
| Kurtosis | 2.22 |
Evolent Health Backtested Returns
Evolent Health secures Sharpe Ratio (or Efficiency) of -0.13, which denotes the company had a -0.13 % return per unit of risk over the last 3 months. Evolent Health exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Evolent Health's Variance of 14.86, standard deviation of 3.86, and Mean Deviation of 2.75 to check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.69, which means possible diversification benefits within a given portfolio. As returns on the market increase, Evolent Health's returns are expected to increase less than the market. However, during the bear market, the loss of holding Evolent Health is expected to be smaller as well. At this point, Evolent Health has a negative expected return of -0.47%. Please make sure to confirm Evolent Health's value at risk, as well as the relationship between the accumulation distribution and day typical price , to decide if Evolent Health performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.17 |
Insignificant reverse predictability
Evolent Health has insignificant reverse predictability. Overlapping area represents the amount of predictability between Evolent Health time series from 17th of November 2025 to 1st of January 2026 and 1st of January 2026 to 15th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Evolent Health price movement. The serial correlation of -0.17 indicates that over 17.0% of current Evolent Health price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.17 | |
| Spearman Rank Test | -0.29 | |
| Residual Average | 0.0 | |
| Price Variance | 0.28 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Evolent Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Evolent Health reported net income of (61.62 Million). This is 118.06% lower than that of the Health Care Technology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 110.79% higher than that of the company.
Evolent Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Evolent Health's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Evolent Health could also be used in its relative valuation, which is a method of valuing Evolent Health by comparing valuation metrics of similar companies.Evolent Health is currently under evaluation in net income category among its peers.
Evolent Health ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Evolent Health's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Evolent Health's managers, analysts, and investors.Environmental | Governance | Social |
Evolent Health Institutional Holders
Institutional Holdings refers to the ownership stake in Evolent Health that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Evolent Health's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Evolent Health's value.| Shares | State Street Corp | 2025-06-30 | 3 M | Rock Springs Capital Management Lp | 2025-06-30 | 2.8 M | Ubs Group Ag | 2025-06-30 | 2.8 M | Dimensional Fund Advisors, Inc. | 2025-06-30 | 2.8 M | Geode Capital Management, Llc | 2025-06-30 | 2.7 M | D. E. Shaw & Co Lp | 2025-06-30 | 2.1 M | Healthcare Of Ontario Pension Plan Trust Fund | 2025-06-30 | 1.9 M | Silvercrest Asset Management Group Llc | 2025-06-30 | 1.8 M | Maverick Capital Ltd | 2025-06-30 | 1.4 M | Vanguard Group Inc | 2025-06-30 | 10.9 M | Cadian Capital Management Lp | 2025-06-30 | 10.4 M |
Evolent Fundamentals
| Return On Equity | -0.12 | ||||
| Return On Asset | 0.0012 | ||||
| Profit Margin | (0.06) % | ||||
| Operating Margin | 0 % | ||||
| Current Valuation | 1.28 B | ||||
| Shares Outstanding | 111.6 M | ||||
| Shares Owned By Insiders | 1.65 % | ||||
| Shares Owned By Institutions | 98.35 % | ||||
| Number Of Shares Shorted | 19.2 M | ||||
| Price To Earning | (13.88) X | ||||
| Price To Book | 0.37 X | ||||
| Price To Sales | 0.16 X | ||||
| Revenue | 2.55 B | ||||
| Gross Profit | 378.34 M | ||||
| EBITDA | 84.85 M | ||||
| Net Income | (61.62 M) | ||||
| Cash And Equivalents | 104.2 M | ||||
| Cash Per Share | 1.57 X | ||||
| Total Debt | 713.67 M | ||||
| Debt To Equity | 0.56 % | ||||
| Current Ratio | 1.03 X | ||||
| Book Value Per Share | 7.55 X | ||||
| Cash Flow From Operations | 18.77 M | ||||
| Short Ratio | 6.59 X | ||||
| Earnings Per Share | (1.57) X | ||||
| Price To Earnings To Growth | (1.37) X | ||||
| Target Price | 8.5 | ||||
| Number Of Employees | 4.5 K | ||||
| Beta | 0.24 | ||||
| Market Capitalization | 323.56 M | ||||
| Total Asset | 2.54 B | ||||
| Retained Earnings | (780.82 M) | ||||
| Working Capital | (108.38 M) | ||||
| Current Asset | 184.46 M | ||||
| Current Liabilities | 59.51 M | ||||
| Net Asset | 2.54 B |
About Evolent Health Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Evolent Health's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Evolent Health using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Evolent Health based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out For more detail on how to invest in Evolent Stock please use our How to Invest in Evolent Health guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is there potential for Health Care Technology market expansion? Will Evolent introduce new products? Factors like these will boost the valuation of Evolent Health. Projected growth potential of Evolent fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Evolent Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.57) | Revenue Per Share | Quarterly Revenue Growth (0.23) | Return On Assets | Return On Equity |
Understanding Evolent Health requires distinguishing between market price and book value, where the latter reflects Evolent's accounting equity. The concept of intrinsic value - what Evolent Health's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Evolent Health's price substantially above or below its fundamental value.
It's important to distinguish between Evolent Health's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Evolent Health should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Evolent Health's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.